Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Cannabidiol | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Cannabidiol | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Cannabidiol | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Cannabidiol | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | Cannabidiol | hsa00190 | Oxidative phosphorylation | 3.74E-02 | 5 | Q16718, P19404, P12074, Q13488, O14521 | NDUFA5, NDUFV2, COX6A1, TCIRG1, SDHD | More | | Cannabidiol | hsa00220 | Arginine biosynthesis | 1.77E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Cannabidiol | hsa00230 | Purine metabolism | 1.81E-02 | 2 | P20839, Q02153 | IMPDH1, GUCY1B3 | More | | Cannabidiol | hsa00260 | Glycine, serine and threonine metabolism | 1.99E-02 | 1 | P22557 | ALAS2 | More | | Cannabidiol | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | | Cannabidiol | hsa00480 | Glutathione metabolism | 2.31E-02 | 1 | P22352 | GPX3 | More | | Cannabidiol | hsa00500 | Starch and sucrose metabolism | 9.22E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Cannabidiol | hsa00510 | N-Glycan biosynthesis | 3.01E-02 | 1 | O94777 | DPM2 | More | | Cannabidiol | hsa00512 | Mucin type O-glycan biosynthesis | 2.28E-03 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Cannabidiol | hsa00514 | Other types of O-glycan biosynthesis | 1.83E-03 | 4 | P15907, O15294, Q8N4A0, Q9NY28 | ST6GAL1, OGT, GALNT4, GALNT8 | More | | Cannabidiol | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 3.56E-02 | 1 | Q9Y2C2 | UST | More | | Cannabidiol | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Cannabidiol | hsa00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 7.16E-04 | 2 | O94777, Q14442 | DPM2, PIGH | More | | Cannabidiol | hsa00565 | Ether lipid metabolism | 3.00E-03 | 1 | Q8N661 | TMEM86B | More | | Cannabidiol | hsa00590 | Arachidonic acid metabolism | 1.43E-03 | 3 | P11712, P22352, P09960 | CYP2C9, GPX3, LTA4H | More | | Cannabidiol | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Cannabidiol | hsa00630 | Glyoxylate and dicarboxylate metabolism | 5.72E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Cannabidiol | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Cannabidiol | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Cannabidiol | hsa00830 | Retinol metabolism | 2.17E-03 | 4 | P00325, P00352, Q9BPW9, O75911 | ADH1B, ALDH1A1, DHRS9, DHRS3 | More | | Cannabidiol | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | Cannabidiol | hsa00920 | Sulfur metabolism | 3.18E-02 | 1 | Q16762 | TST | More | | Cannabidiol | hsa00970 | Aminoacyl-tRNA biosynthesis | 9.22E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Cannabidiol | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.67E-04 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Cannabidiol | hsa00982 | Drug metabolism - cytochrome P450 | 6.67E-04 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Cannabidiol | hsa00983 | Drug metabolism - other enzymes | 2.99E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Cannabidiol | hsa01100 | Metabolic pathways | 4.53E-03 | 4 | P36969, O94777, P04406, Q06055 | GPX4, DPM2, GAPDH, ATP5G2 | More | | Cannabidiol | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Cannabidiol | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Cannabidiol | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Cannabidiol | hsa01522 | Endocrine resistance | 4.74E-02 | 3 | P22694, P10415, Q13323 | PRKACB, BCL2, BIK | More | | Cannabidiol | hsa01524 | Platinum drug resistance | 1.13E-03 | 6 | P10415, Q13489, P98170, P78417, P23025, P43246 | BCL2, BIRC3, BIRC4, GSTO1, XPA, MSH2 | More | | Cannabidiol | hsa02010 | ABC transporters | 2.40E-03 | 2 | P45844, Q8IZY2 | ABCG1, ABCA7 | More | | Cannabidiol | hsa03008 | Ribosome biogenesis in eukaryotes | 4.44E-04 | 7 | Q9NYH9, P19784, P67870, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, CSNK2A2, CSNK2B, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Cannabidiol | hsa03010 | Ribosome | 3.22E-03 | 2 | Q9UHA3, P50914 | RSL24D1, RPL14 | More | | Cannabidiol | hsa03013 | RNA transport | 5.13E-08 | 20 | O14980, P52298, Q09161, O14893, P61326, Q15287, Q9UBU9, Q7Z3B4, P35658, P63279, Q14152, P55884, O15371, O75822, P78345, P20042, Q14240, Q9Y6A5, Q14232, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, RNPS1, NXF1, NUP54, NUP214, UBE2I, EIF3A, EIF3B, EIF3D, EIF3J, RPP38, EIF2S2, EIF4A2, TACC3, EIF2B1, FXR1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P21462 | FPR1 | fMet-Leu-Phe receptor | O14980 | XPO1 | Exportin-1 | -0.742 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.888 | P21462 | FPR1 | fMet-Leu-Phe receptor | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | -0.874 | P51684 | CCR6 | C-C chemokine receptor type 6 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.924 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | 0.742 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | -0.78 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.853 | P21462 | FPR1 | fMet-Leu-Phe receptor | O14893 | GEMIN2 | Gem-associated protein 2 | -0.87 | P51684 | CCR6 | C-C chemokine receptor type 6 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.771 | P21462 | FPR1 | fMet-Leu-Phe receptor | P61326 | MAGOH | Protein mago nashi homolog | -0.835 | P51684 | CCR6 | C-C chemokine receptor type 6 | P61326 | MAGOH | Protein mago nashi homolog | 0.704 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Q15287 | RNPS1 | RNA-binding protein with serine-rich domain 1 | 0.756 | P45880 | VDAC2 | Voltage-dependent anion-selective channel protein 2 | Q15287 | RNPS1 | RNA-binding protein with serine-rich domain 1 | 0.709 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Q9UBU9 | NXF1 | Nuclear RNA export factor 1 | 0.723 | P45880 | VDAC2 | Voltage-dependent anion-selective channel protein 2 | Q9UBU9 | NXF1 | Nuclear RNA export factor 1 | 0.701 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.774 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q7Z3B4 | NUP54 | Nucleoporin p54 | -0.903 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.811 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P35658 | NUP214 | Nuclear pore complex protein Nup214 | -0.725 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P35658 | NUP214 | Nuclear pore complex protein Nup214 | -0.751 | P21462 | FPR1 | fMet-Leu-Phe receptor | P35658 | NUP214 | Nuclear pore complex protein Nup214 | 0.971 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.736 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.734 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | -0.89 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.701 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P55884 | EIF3B | Eukaryotic translation initiation factor 3 subunit B | -0.731 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | O15371 | EIF3D | Eukaryotic translation initiation factor 3 subunit D | 0.77 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | 0.837 | P21462 | FPR1 | fMet-Leu-Phe receptor | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | -0.953 | P51684 | CCR6 | C-C chemokine receptor type 6 | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | 0.711 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P78345 | RPP38 | Ribonuclease P protein subunit p38 | 0.852 | P51684 | CCR6 | C-C chemokine receptor type 6 | P78345 | RPP38 | Ribonuclease P protein subunit p38 | 0.861 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P20042 | EIF2S2 | Eukaryotic translation initiation factor 2 subunit 2 | 0.733 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14240 | EIF4A2 | Eukaryotic initiation factor 4A-II | -0.721 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.812 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | 0.904 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.732 | P45880 | VDAC2 | Voltage-dependent anion-selective channel protein 2 | Q14232 | EIF2B1 | Translation initiation factor eIF-2B subunit alpha | 0.703 | P21462 | FPR1 | fMet-Leu-Phe receptor | P51114 | FXR1 | Fragile X mental retardation syndrome-related protein 1 | -0.713 |
| Cannabidiol | hsa03015 | mRNA surveillance pathway | 7.29E-03 | 6 | O60942, O43148, Q15287, Q9UBU9, P52298, Q53GS7 | RNGTT, RNMT, RNPS1, NXF1, NCBP2, GLE1 | More | | Cannabidiol | hsa03020 | RNA polymerase | 1.31E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Cannabidiol | hsa03040 | Spliceosome | 2.14E-09 | 19 | Q14562, O43143, O60508, Q99633, P08579, Q15427, P26368, P38159, P61978, Q13595, Q07955, Q01130, P84103, Q13243, Q9UMS4, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, PRPF18, SNRPB2, SF3B4, U2AF2, RBMX, HNRPK, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, PRPF19, HSPA8, WBP11, PPIH, ASCC3L1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P46091 | GPR1 | Chemerin-like receptor 2 | Q14562 | DHX8 | ATP-dependent RNA helicase DHX8 | -0.819 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.76 | P46091 | GPR1 | Chemerin-like receptor 2 | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.816 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.812 | P46091 | GPR1 | Chemerin-like receptor 2 | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.778 | P46091 | GPR1 | Chemerin-like receptor 2 | Q99633 | PRPF18 | Pre-mRNA-splicing factor 18 | -0.711 | P21796 | VDAC1 | Voltage-dependent anion-selective channel protein 1 | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | 0.793 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.822 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Q15427 | SF3B4 | Splicing factor 3B subunit 4 | 0.71 | P21796 | VDAC1 | Voltage-dependent anion-selective channel protein 1 | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | 0.772 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.751 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P38159 | RBMX | RNA-binding motif protein, X chromosome | 0.733 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P61978 | HNRPK | Heterogeneous nuclear ribonucleoprotein K | 0.784 | P21796 | VDAC1 | Voltage-dependent anion-selective channel protein 1 | Q13595 | TRA2A | Transformer-2 protein homolog alpha | 0.785 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.74 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.753 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | -0.749 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.798 | P46091 | GPR1 | Chemerin-like receptor 2 | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.746 | P21796 | VDAC1 | Voltage-dependent anion-selective channel protein 1 | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | 0.821 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.773 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.822 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UMS4 | PRPF19 | Pre-mRNA-processing factor 19 | 0.703 | P21796 | VDAC1 | Voltage-dependent anion-selective channel protein 1 | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.741 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.743 | P21796 | VDAC1 | Voltage-dependent anion-selective channel protein 1 | O43447 | PPIH | Peptidyl-prolyl cis-trans isomerase H | 0.795 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43447 | PPIH | Peptidyl-prolyl cis-trans isomerase H | -0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.745 |
| Cannabidiol | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | | Cannabidiol | hsa03060 | Protein export | 9.84E-06 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Cannabidiol | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | | Cannabidiol | hsa04014 | Ras signaling pathway | 3.06E-03 | 11 | P42338, P20827, P49767, Q13009, Q7LDG7, Q14644, P0DP23, P62873, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, RASA3, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Cannabidiol | hsa04015 | Rap1 signaling pathway | 1.45E-04 | 14 | P20827, P49767, P63261, Q96FS4, P11215, P25116, Q8TEU7, Q13009, Q7LDG7, P42338, P0DP23, P08514, P17252, P19174 | EFNA1, VEGFC, ACTG1, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, RASGRP2, PIK3CB, CALM1, ITGA2B, PRKCA, PLCG1 | More | | Cannabidiol | hsa04020 | Calcium signaling pathway | 2.59E-06 | 12 | Q96DU7, P45880, Q16566, Q13557, P17252, P21860, O15399, P25116, P0DP23, P51828, P23634, P49767 | ITPKC, VDAC2, CAMK4, CAMK2D, PRKCA, ERBB3, GRIN2D, F2R, CALM1, ADCY7, ATP2B4, VEGFC | More | | Cannabidiol | hsa04022 | cGMP-PKG signaling pathway | 4.72E-02 | 4 | Q99941, P23634, P51828, P45880 | CREBL1, ATP2B4, ADCY7, VDAC2 | More | | Cannabidiol | hsa04024 | cAMP signaling pathway | 3.11E-03 | 8 | P63092, P26678, P0DP23, P23634, P61586, Q16566, O15399, P25116 | GNAS, PLN, CALM1, ATP2B4, RHOA, CAMK4, GRIN2D, F2R | More | | Cannabidiol | hsa04060 | Cytokine-cytokine receptor interaction | 3.17E-05 | 17 | P14784, P27930, P14778, P08476, P26842, Q06643, Q13651, P25024, P25025, Q9UBD3, P47992, P01375, P09341, P18510, P09603, P01730, Q93038 | IL2RB, IL1R2, IL1R1, INHBA, CD27, LTB, IL10RA, CXCR1, CXCR2, XCL2, XCL1, TNF, CXCL1, IL1RN, CSF1, CD4, TNFRSF25 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.779 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.837 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.807 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P08476 | INHBA | Inhibin beta A chain | -0.798 | P06239 | LCK | Tyrosine-protein kinase Lck | P26842 | CD27 | CD27 antigen | 0.817 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P26842 | CD27 | CD27 antigen | 0.706 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.881 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.779 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.774 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.794 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | -0.774 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | 0.715 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | 0.836 | P06239 | LCK | Tyrosine-protein kinase Lck | P47992 | XCL1 | Lymphotactin | 0.715 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P47992 | XCL1 | Lymphotactin | 0.836 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P01375 | TNF | Tumor necrosis factor | -0.856 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.762 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.839 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P18510 | IL1RN | Interleukin-1 receptor antagonist protein | -0.743 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P18510 | IL1RN | Interleukin-1 receptor antagonist protein | -0.787 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P09603 | CSF1 | Macrophage colony-stimulating factor 1 | -0.715 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.756 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | Q93038 | TNFRSF25 | Tumor necrosis factor receptor superfamily member 25 | 0.795 |
| Cannabidiol | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 5.72E-05 | 10 | Q8NHW4, P09341, P25024, P25025, P61073, P47992, Q9UBD3, Q13651, P14784, P01375 | CCL4L2, CXCL1, CXCR1, CXCR2, CXCR4, XCL1, XCL2, IL10RA, IL2RB, TNF | More | | Cannabidiol | hsa04062 | Chemokine signaling pathway | 3.74E-06 | 18 | P25024, P25025, P09341, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P49841, Q8WYR1 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, GSK3B, PIK3R5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.779 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P47992 | XCL1 | Lymphotactin | 0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | 0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.728 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.71 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | P06239 | LCK | Tyrosine-protein kinase Lck | P43250 | GRK6 | G protein-coupled receptor kinase 6 | -0.702 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| Cannabidiol | hsa04064 | NF-kappa B signaling pathway | 2.71E-05 | 18 | P10415, P51617, O00463, Q13546, P14778, P01584, Q04759, Q9UDY8, Q13077, P67870, P07948, P06239, P63279, P24522, Q8NHW4, P09341, Q06643, Q9NQC7 | BCL2, IRAK1, TRAF5, RIPK1, IL1R1, IL1B, PRKCQ, MALT1, TRAF1, CSNK2B, LYN, LCK, UBE2I, GADD45A, CCL4L2, CXCL1, LTB, CYLD | More | | Cannabidiol | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | Cannabidiol | hsa04071 | Sphingolipid signaling pathway | 9.73E-05 | 9 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2 | More | | Cannabidiol | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | | Cannabidiol | hsa04080 | Neuroactive ligand-receptor interaction | 6.43E-06 | 11 | P08311, P28472, Q15722, P21453, Q9H228, O00398, Q01726, P41968, P21462, P21730, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, MC1R, MC3R, FPR1, C5AR1, ADRB2 | More | | Cannabidiol | hsa04110 | Cell cycle | 4.67E-03 | 5 | Q09472, P24522, P49918, P42773, P01106 | EP300, GADD45A, CDKN1C, CDKN2C, MYC | More | | Cannabidiol | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Cannabidiol | hsa04120 | Ubiquitin mediated proteolysis | 4.91E-05 | 8 | Q14145, Q13042, Q13191, P62837, Q15751, O95071, Q7Z6Z7, P0CG47 | KEAP1, CDC16, CBLB, UBE2D2, HERC1, UBR5, HUWE1, UBB | More | | Cannabidiol | hsa04122 | Sulfur relay system | 3.18E-02 | 1 | Q16762 | TST | More | | Cannabidiol | hsa04137 | Mitophagy - animal | 6.72E-04 | 4 | P19784, P67870, Q07817, P0CG47 | CSNK2A2, CSNK2B, BCL2L1, UBB | More | | Cannabidiol | hsa04140 | Autophagy - animal | 4.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | Cannabidiol | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | | Cannabidiol | hsa04142 | Lysosome | 1.96E-02 | 3 | Q9UBR2, P34059, P17900 | CTSZ, GALNS, GM2A | More | | Cannabidiol | hsa04144 | Endocytosis | 2.62E-04 | 12 | Q13191, P0DMV8, P11142, Q9H444, O75351, Q9NZZ3, P62491, P42566, P61073, P43250, P84022, Q9Y5X3 | CBLB, HSPA1A, HSPA8, CHMP4B, VPS4B, CHMP5, RAB11A, EPS15, CXCR4, GRK6, SMAD3, SNX5 | More | | Cannabidiol | hsa04145 | Phagosome | 9.60E-06 | 11 | P63261, Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P27824, P13765 | ACTG1, NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, CANX, HLA-DOB | More | | Cannabidiol | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Cannabidiol | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | Cannabidiol | hsa04213 | Longevity regulating pathway - multiple species | 4.34E-02 | 2 | P51828, P0DMV8 | ADCY7, HSPA1A | More | | Cannabidiol | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Cannabidiol | hsa04217 | Necroptosis | 7.97E-06 | 17 | P01375, P01568, P23458, P48023, Q13489, Q9NQC7, Q13546, Q14765, P07384, P0C0S5, Q6FI13, Q99878, P10415, Q9H444, O43633, Q9NZZ3, O75351 | TNF, IFNA21, JAK1, FASLG, BIRC3, CYLD, RIPK1, STAT4, CAPN1, H2AFZ, H2AC18; H2AC19, H2AC14, BCL2, CHMP4B, CHMP2A, CHMP5, VPS4B | More | | Cannabidiol | hsa04260 | Cardiac muscle contraction | 4.49E-02 | 3 | P67936, P13073, P12074 | TPM4, COX4I1, COX6A1 | More | | Cannabidiol | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.69E-04 | 13 | P07550, P51828, P22694, Q99941, P18848, Q13362, Q16537, P0DP23, Q13557, P17252, P10415, P20020, P23634 | ADRB2, ADCY7, PRKACB, CREBL1, ATF4, PPP2R5C, PPP2R5E, CALM1, CAMK2D, PRKCA, BCL2, ATP2B1, ATP2B4 | More | | Cannabidiol | hsa04270 | Vascular smooth muscle contraction | 2.96E-02 | 4 | P0DP24, P51828, P35579, P35318 | CALM2, ADCY7, MYH9, ADM | More | | Cannabidiol | hsa04310 | Wnt signaling pathway | 9.34E-04 | 7 | P84022, P61586, P30279, Q13485, O43318, P19784, P67870 | SMAD3, RHOA, CCND2, SMAD4, MAP3K7, CSNK2A2, CSNK2B | More | | Cannabidiol | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | Cannabidiol | hsa04340 | Hedgehog signaling pathway | 4.20E-04 | 4 | P22694, Q13635, Q9Y496, P10415 | PRKACB, PTCH1, KIF3A, BCL2 | More | | Cannabidiol | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Cannabidiol | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Cannabidiol | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Cannabidiol | hsa04371 | Apelin signaling pathway | 2.07E-06 | 10 | P62873, P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022, Q16566, P0DP23 | GNB1, GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3, CAMK4, CALM1 | More | | Cannabidiol | hsa04390 | Hippo signaling pathway | 9.73E-04 | 6 | P63261, P84022, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD3, SMAD4, LEF1, SNAI2, BIRC3 | More | | Cannabidiol | hsa04510 | Focal adhesion | 5.93E-04 | 10 | O75369, Q15942, O14986, P17252, P61586, Q16363, Q13489, P10415, P49767, P63261 | FLNB, ZYX, PIP5K1B, PRKCA, RHOA, LAMA4, BIRC3, BCL2, VEGFC, ACTG1 | More | | Cannabidiol | hsa04512 | ECM-receptor interaction | 3.73E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Cannabidiol | hsa04514 | Cell adhesion molecules | 8.19E-03 | 3 | P16109, P56750, O00501 | SELP, CLDN17, CLDN5 | More | | Cannabidiol | hsa04520 | Adherens junction | 1.66E-04 | 7 | Q13485, Q9UJU2, O43623, P19784, P67870, P61586, P63261 | SMAD4, LEF1, SNAI2, CSNK2A2, CSNK2B, RHOA, ACTG1 | More | | Cannabidiol | hsa04530 | Tight junction | 2.47E-05 | 5 | Q8TEU7, P16989, P56750, O00501, Q14247 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN | More | | Cannabidiol | hsa04540 | Gap junction | 3.27E-03 | 5 | P17252, P22694, Q13509, P68371, Q14643 | PRKCA, PRKACB, TUBB3, TUBB2C, ITPR1 | More | | Cannabidiol | hsa04610 | Complement and coagulation cascades | 1.03E-03 | 3 | P25116, P09871, P0C0L4 | F2R, C1S, C4A | More | | Cannabidiol | hsa04611 | Platelet activation | 5.18E-05 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | | Cannabidiol | hsa04612 | Antigen processing and presentation | 5.26E-07 | 10 | P13765, P48382, P01730, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.7 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P48382 | RFX5 | DNA-binding protein RFX5 | 0.81 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.743 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.8 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.8 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.85 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.721 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.813 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P01375 | TNF | Tumor necrosis factor | -0.856 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 |
| Cannabidiol | hsa04613 | Neutrophil extracellular trap formation | 3.77E-06 | 25 | P17252, P16109, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, Q6FI13, Q93077, P62807, P33778, Q16778, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P08514, P21462, P07359 | PRKCA, SELP, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, ITGA2B, FPR1, GP1BA | More | | Cannabidiol | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Cannabidiol | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Cannabidiol | hsa04623 | Cytosolic DNA-sensing pathway | 5.88E-04 | 4 | P01584, P01568, Q13546, Q8NHW4 | IL1B, IFNA21, RIPK1, CCL4L2 | More | | Cannabidiol | hsa04630 | JAK-STAT signaling pathway | 4.43E-02 | 3 | P01106, Q09472, P16871 | MYC, EP300, IL7R | More | | Cannabidiol | hsa04640 | Hematopoietic cell lineage | 6.36E-09 | 15 | P13612, P14778, P27930, P20023, P25063, P04234, P07766, P09693, P01732, P01730, P09564, P16871, P13765, P20036, P09603 | ITGA4, IL1R1, IL1R2, CR2, CD24, CD3D, CD3E, CD3G, CD8A, CD4, CD7, IL7R, HLA-DOB, HLA-DPA1, CSF1 | More | | Cannabidiol | hsa04650 | Natural killer cell mediated cytotoxicity | 3.14E-12 | 15 | P16298, P50591, P01375, P78314, P06239, O60880, P20963, Q02750, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P11511 | CYP19A1 | Aromatase | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.706 | P11511 | CYP19A1 | Aromatase | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.701 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P01375 | TNF | Tumor necrosis factor | -0.856 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.812 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P11511 | CYP19A1 | Aromatase | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.783 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.85 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.824 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.766 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.8 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.8 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Cannabidiol | hsa04657 | IL-17 signaling pathway | 2.31E-03 | 8 | P08238, Q07955, P19875, P14780, Q9UJX4, P04141, P80188, P01375 | HSP90AB1, SFRS1, CXCL2, MMP9, ANAPC5, CSF2, LCN2, TNF | More | | Cannabidiol | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-09 | 13 | Q04759, P07766, P04234, P20963, P09693, P01730, P06239, P23771, Q9UL17, P14784, P13765, P20036, Q13761 | PRKCQ, CD3E, CD3D, CD247, CD3G, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, HLA-DPA1, RUNX3 | More | | Cannabidiol | hsa04659 | Th17 cell differentiation | 5.59E-10 | 18 | P25963, Q04759, P19174, P01730, P06239, P14784, P13765, P20036, P14778, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P04234, P20963 | NFKBIA, PRKCQ, PLCG1, CD4, LCK, IL2RB, HLA-DOB, HLA-DPA1, IL1R1, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD3D, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.728 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.756 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q9Y5S1 | TRPV2 | Transient receptor potential cation channel subfamily V member 2 | P20036 | HLA-DPA1 | HLA class II histocompatibility antigen, DP alpha 1 chain | 0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.807 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.731 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.769 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.721 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.777 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q9Y5S1 | TRPV2 | Transient receptor potential cation channel subfamily V member 2 | P04234 | CD3D | T-cell surface glycoprotein CD3 delta chain | 0.704 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.758 |
| Cannabidiol | hsa04660 | T cell receptor signaling pathway | 7.54E-06 | 13 | P01375, Q04759, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Cannabidiol | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Cannabidiol | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Cannabidiol | hsa04666 | Fc gamma R-mediated phagocytosis | 1.44E-03 | 6 | P23528, P49006, P06396, O14494, P14598, P17252 | CFL1, MARCKSL1, GSN, PLPP1, NCF1, PRKCA | More | | Cannabidiol | hsa04668 | TNF signaling pathway | 4.29E-03 | 7 | P01375, Q99941, P18848, P19875, P01584, P14780, O95429 | TNF, CREBL1, ATF4, CXCL2, IL1B, MMP9, BAG4 | More | | Cannabidiol | hsa04672 | Intestinal immune network for IgA production | 1.43E-02 | 4 | P29965, P10747, P13765, P20036 | CD40LG, CD28, HLA-DOB, HLA-DPA1 | More | | Cannabidiol | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Cannabidiol | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | | Cannabidiol | hsa04720 | Long-term potentiation | 2.27E-05 | 8 | P17252, Q16566, P16298, P0DP23, P51812, O15399, Q02750, Q14643 | PRKCA, CAMK4, PPP3CB, CALM1, RPS6KA3, GRIN2D, MAP2K1, ITPR1 | More | | Cannabidiol | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Cannabidiol | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | | Cannabidiol | hsa04724 | Glutamatergic synapse | 4.63E-06 | 8 | P48058, O15399, P43003, P63092, P62873, P63218, P50151, P15104 | GRIA4, GRIN2D, SLC1A3, GNAS, GNB1, GNG5, GNG10, GLUL | More | | Cannabidiol | hsa04725 | Cholinergic synapse | 3.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | Cannabidiol | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | Cannabidiol | hsa04727 | GABAergic synapse | 1.69E-03 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Cannabidiol | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Cannabidiol | hsa04730 | Long-term depression | 3.10E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Cannabidiol | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Cannabidiol | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Cannabidiol | hsa04744 | Phototransduction | 2.20E-04 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Cannabidiol | hsa04750 | Inflammatory mediator regulation of TRP channels | 8.09E-03 | 4 | P01584, P51828, Q13557, Q9Y5S1 | IL1B, ADCY7, CAMK2D, TRPV2 | More | | Cannabidiol | hsa04810 | Regulation of actin cytoskeleton | 2.58E-02 | 3 | Q15746, P08514, P25116 | MYLK, ITGA2B, F2R | More | | Cannabidiol | hsa04911 | Insulin secretion | 1.48E-02 | 3 | P51828, Q99941, Q13557 | ADCY7, CREBL1, CAMK2D | More | | Cannabidiol | hsa04912 | GnRH signaling pathway | 4.42E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | Cannabidiol | hsa04913 | Ovarian steroidogenesis | 1.27E-03 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Cannabidiol | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Cannabidiol | hsa04915 | Estrogen signaling pathway | 2.52E-03 | 7 | Q99941, P51828, P07900, P0DMV8, P11142, P0DP24, Q15788 | CREBL1, ADCY7, HSP90AA1, HSPA1A, HSPA8, CALM2, NCOA1 | More | | Cannabidiol | hsa04916 | Melanogenesis | 4.89E-04 | 6 | P0DP23, Q9UJU2, P17252, P49841, Q01726, P04628 | CALM1, LEF1, PRKCA, GSK3B, MC1R, WNT1 | More | | Cannabidiol | hsa04918 | Thyroid hormone synthesis | 3.62E-02 | 1 | P22352 | GPX3 | More | | Cannabidiol | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | Cannabidiol | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Cannabidiol | hsa04924 | Renin secretion | 2.90E-04 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Cannabidiol | hsa04925 | Aldosterone synthesis and secretion | 5.60E-06 | 9 | Q14643, Q99941, P51828, P0DP23, P17252, Q16566, Q13557, P20020, P23634 | ITPR1, CREBL1, ADCY7, CALM1, PRKCA, CAMK4, CAMK2D, ATP2B1, ATP2B4 | More | | Cannabidiol | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Cannabidiol | hsa04927 | Cortisol synthesis and secretion | 1.27E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Cannabidiol | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.02E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | Cannabidiol | hsa04932 | Non-alcoholic fatty liver disease | 6.66E-04 | 9 | P01375, P49841, O43521, P48023, O75460, P01584, P13073, P12074, O15239 | TNF, GSK3B, BCL2L11, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA1 | More | | Cannabidiol | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.45E-05 | 8 | P84022, Q13485, P10415, P42338, Q12778, P49767, P17252, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, FOXO1, VEGFC, PRKCA, PLCG1 | More | | Cannabidiol | hsa04934 | Cushing syndrome | 5.32E-04 | 7 | Q14643, Q99941, P51828, P22694, O15169, Q13557, P04628 | ITPR1, CREBL1, ADCY7, PRKACB, AXIN1, CAMK2D, WNT1 | More | | Cannabidiol | hsa04940 | Type I diabetes mellitus | 3.01E-04 | 3 | P48023, P20036, P01375 | FASLG, HLA-DPA1, TNF | More | | Cannabidiol | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Cannabidiol | hsa04966 | Collecting duct acid secretion | 2.32E-03 | 3 | P02730, P00918, Q9Y666 | SLC4A1, CA2, SLC12A7 | More | | Cannabidiol | hsa04970 | Salivary secretion | 2.77E-06 | 8 | P07550, P22694, Q14643, P20020, P23634, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1, CAMP | More | | Cannabidiol | hsa04971 | Gastric acid secretion | 1.87E-03 | 6 | P51828, P17252, P15311, P63261, P0DP23, Q13557 | ADCY7, PRKCA, VIL2, ACTG1, CALM1, CAMK2D | More | | Cannabidiol | hsa04972 | Pancreatic secretion | 6.98E-05 | 7 | Q14643, P20020, P17252, P63092, Q08828, P62491, P61586 | ITPR1, ATP2B1, PRKCA, GNAS, ADCY1, RAB11A, RHOA | More | | Cannabidiol | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Cannabidiol | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Cannabidiol | hsa05010 | Alzheimer disease | 1.32E-04 | 17 | Q92542, O15239, P05496, Q06055, P13073, P12074, Q00535, O75460, P0DP23, P04406, P01584, O95197, O15169, P67870, P45880, P28070, P62195 | NCSTN, NDUFA1, ATP5G1, ATP5G2, COX4I1, COX6A1, CDK5, ERN1, CALM1, GAPDH, IL1B, RTN3, AXIN1, CSNK2B, VDAC2, PSMB4, PSMC5 | More | | Cannabidiol | hsa05012 | Parkinson disease | 2.95E-03 | 5 | P19404, P12074, Q06055, P45880, P62195 | NDUFV2, COX6A1, ATP5G2, VDAC2, PSMC5 | More | | Cannabidiol | hsa05014 | Amyotrophic lateral sclerosis | 1.64E-02 | 9 | O15399, P10415, Q06055, Q13509, P68371, P62195, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, ATP5G2, TUBB3, TUBB2C, PSMC5, GLE1, ACTG1, NXF2; NXF2B | More | | Cannabidiol | hsa05016 | Huntington disease | 3.83E-03 | 5 | P19404, P12074, Q06055, P45880, P62195 | NDUFV2, COX6A1, ATP5G2, VDAC2, PSMC5 | More | | Cannabidiol | hsa05020 | Prion disease | 9.09E-05 | 14 | P01584, P46531, P11142, P19404, P05496, Q06055, P12074, O15399, Q9NZJ5, P21796, P45880, P62195, Q71U36, Q99941 | IL1B, NOTCH1, HSPA8, NDUFV2, ATP5G1, ATP5G2, COX6A1, GRIN2D, EIF2AK3, VDAC1, VDAC2, PSMC5, TUBA1A, CREBL1 | More | | Cannabidiol | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.97E-02 | 10 | O15399, Q13509, P68371, P10415, Q06055, Q13561, P07384, P04628, P0DP23, P62195 | GRIN2D, TUBB3, TUBB2C, BCL2, ATP5G2, DCTN2, CAPN1, WNT1, CALM1, PSMC5 | More | | Cannabidiol | hsa05031 | Amphetamine addiction | 1.61E-03 | 7 | O15399, P0DP23, Q16566, P22694, P18848, P17252, Q13547 | GRIN2D, CALM1, CAMK4, PRKACB, ATF4, PRKCA, HDAC1 | More | | Cannabidiol | hsa05032 | Morphine addiction | 3.27E-08 | 7 | P62873, Q07343, P48169, P78334, P63092, P32298, P43250 | GNB1, PDE4B, GABRA4, GABRE, GNAS, GRK4, GRK6 | More | | Cannabidiol | hsa05034 | Alcoholism | 3.96E-06 | 13 | P07101, Q16566, P0DP24, P0DP23, Q96RR4, P62873, P0C0S5, Q93077, P62807, P33778, O60814, P84243, P68431 | TH, CAMK4, CALM2, CALM1, CAMKK2, GNB1, H2AFZ, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3F3A, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Cannabidiol | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | Cannabidiol | hsa05130 | Pathogenic Escherichia coli infection | 7.39E-03 | 4 | Q14247, P56750, O00501, P25116 | CTTN, CLDN17, CLDN5, F2R | More | | Cannabidiol | hsa05132 | Salmonella infection | 9.92E-08 | 14 | P51617, P25963, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, NFKBIA, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | Cannabidiol | hsa05133 | Pertussis | 1.02E-05 | 6 | P11215, P0DP23, P23528, P09871, P0C0L4, Q02556 | ITGAM, CALM1, CFL1, C1S, C4A, IRF8 | More | | Cannabidiol | hsa05134 | Legionellosis | 4.34E-02 | 2 | Q9NR31, P0DMV8 | SAR1A, HSPA1A | More | | Cannabidiol | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Cannabidiol | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, O60603, P49006, P51617, Q15080 | NCF1, TLR2, MARCKSL1, IRAK1, NCF4 | More | | Cannabidiol | hsa05142 | Chagas disease | 3.80E-03 | 4 | P01375, P30679, P48023, P04234 | TNF, GNA15, FASLG, CD3D | More | | Cannabidiol | hsa05143 | African trypanosomiasis | 4.76E-05 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Cannabidiol | hsa05144 | Malaria | 1.30E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Cannabidiol | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | | Cannabidiol | hsa05146 | Amoebiasis | 5.29E-07 | 11 | Q13751, P09341, P19875, P14778, P27930, P01375, P05089, P30679, P22694, P12814, P08311 | LAMB3, CXCL1, CXCL2, IL1R1, IL1R2, TNF, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Cannabidiol | hsa05150 | Staphylococcus aureus infection | 1.04E-03 | 7 | P21730, P21462, O75015, P59665, P59666, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | | Cannabidiol | hsa05152 | Tuberculosis | 5.68E-03 | 9 | Q13488, P0DP23, P48382, O60603, P10415, P13765, P01568, Q9UDY8, P51617 | TCIRG1, CALM1, RFX5, TLR2, BCL2, HLA-DOB, IFNA21, MALT1, IRAK1 | More | | Cannabidiol | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Cannabidiol | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | Cannabidiol | hsa05162 | Measles | 3.10E-03 | 8 | P23458, P0DMV8, P11142, Q13191, Q9NZJ5, Q9NP90, P30279, O43318 | JAK1, HSPA1A, HSPA8, CBLB, EIF2AK3, RAB9B, CCND2, MAP3K7 | More | | Cannabidiol | hsa05163 | Human cytomegalovirus infection | 2.08E-04 | 19 | P01375, P62873, P63218, P50151, P0DP23, P61586, Q8NHW4, Q08828, P23458, P49841, P14778, P01584, P61073, Q13651, P25025, Q16539, P63092, O00463, P61769 | TNF, GNB1, GNG5, GNG10, CALM1, RHOA, CCL4L2, ADCY1, JAK1, GSK3B, IL1R1, IL1B, CXCR4, IL10RA, CXCR2, MAPK14, GNAS, TRAF5, B2M | More | | Cannabidiol | hsa05166 | Human T-cell leukemia virus 1 infection | 1.68E-03 | 7 | P01106, P04234, P09693, P20036, Q09472, P42773, P01730 | MYC, CD3D, CD3G, HLA-DPA1, EP300, CDKN2C, CD4 | More | | Cannabidiol | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Cannabidiol | hsa05168 | Herpes simplex virus 1 infection | 7.40E-04 | 11 | Q9UKJ0, Q06124, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q9NR11, Q03923, Q9UDV6, P10415 | PILRB, PTPN11, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF302, ZNF85, ZNF212, BCL2 | More | | Cannabidiol | hsa05169 | Epstein-Barr virus infection | 1.01E-06 | 20 | P20023, P13765, P20036, P01106, Q13547, Q92769, P04637, Q13546, O00463, P10415, P07948, Q13761, P24522, O60603, P51617, Q14790, P04234, P07766, P09693, P20963 | CR2, HLA-DOB, HLA-DPA1, MYC, HDAC1, HDAC2, TP53, RIPK1, TRAF5, BCL2, LYN, RUNX3, GADD45A, TLR2, IRAK1, CASP8, CD3D, CD3E, CD3G, CD247 | More | | Cannabidiol | hsa05170 | Human immunodeficiency virus 1 infection | 3.18E-06 | 19 | Q02750, P62873, P62879, P16298, P0DP23, Q05397, P17252, Q13546, O00463, Q14643, P01568, P51617, O60603, P23528, P09693, P10415, Q93034, Q9Y6Q5, P20333 | MAP2K1, GNB1, GNB2, PPP3CB, CALM1, PTK2, PRKCA, RIPK1, TRAF5, ITPR1, IFNA21, IRAK1, TLR2, CFL1, CD3G, BCL2, CUL5, AP1M2, TNFRSF1B | More | | Cannabidiol | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | | Cannabidiol | hsa05200 | Pathways in cancer | 1.48E-05 | 29 | Q13751, P42338, P08238, P19174, Q9UJU2, P17252, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, P98170, P49767, Q12778, P43657, P25116, P62873, P63218, P50151, Q14344, Q7LDG7, P78417, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, LEF1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, BIRC4, VEGFC, FOXO1, P2RY5, F2R, GNB1, GNG5, GNG10, GNA13, RASGRP2, GSTO1, GADD45B, CALM1, IFNA21, IL2RB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | Q13751 | LAMB3 | Laminin subunit beta-3 | -0.732 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.736 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.708 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | 0.749 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.741 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P98170 | BIRC4 | E3 ubiquitin-protein ligase XIAP | -0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.811 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | Q12778 | FOXO1 | Forkhead box protein O1 | -0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.767 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.913 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | O75832 | PSMD10 | 26S proteasome non-ATPase regulatory subunit 10 | P0DP23 | CALM1 | Calmodulin-1 | 0.739 | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| Cannabidiol | hsa05202 | Transcriptional misregulation in cancer | 3.43E-03 | 16 | Q12778, Q15532, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, Q13547, P24522 | FOXO1, SS18, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC1, GADD45A | More | | Cannabidiol | hsa05203 | Viral carcinogenesis | 9.67E-04 | 6 | Q14790, Q09472, Q15283, P62807, P33778, O60814 | CASP8, EP300, RASA2, HIST1H2BC, H2BC3, H2BC12 | More | | Cannabidiol | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Cannabidiol | hsa05205 | Proteoglycans in cancer | 1.39E-03 | 13 | Q13009, Q12955, Q14643, O75369, P14780, P17252, O60603, P01375, P23588, P04628, Q13635, P22694, P08962 | TIAM1, ANK3, ITPR1, FLNB, MMP9, PRKCA, TLR2, TNF, EIF4B, WNT1, PTCH1, PRKACB, CD63 | More | | Cannabidiol | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | Cannabidiol | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Cannabidiol | hsa05212 | Pancreatic cancer | 9.87E-04 | 5 | P42338, P37173, P84022, Q13485, O75293 | PIK3CB, TGFBR2, SMAD3, SMAD4, GADD45B | More | | Cannabidiol | hsa05213 | Endometrial cancer | 3.30E-03 | 4 | O15169, P01106, Q02750, P24522 | AXIN1, MYC, MAP2K1, GADD45A | More | | Cannabidiol | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | Cannabidiol | hsa05216 | Thyroid cancer | 8.83E-04 | 4 | P01106, Q9UJU2, P04637, P24522 | MYC, LEF1, TP53, GADD45A | More | | Cannabidiol | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Cannabidiol | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | Cannabidiol | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Cannabidiol | hsa05226 | Gastric cancer | 4.33E-03 | 5 | Q02750, O15169, P84022, Q13485, P10415 | MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | | Cannabidiol | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.70E-03 | 7 | P07766, P04234, P20963, P09693, P06239, Q04759, P01730 | CD3E, CD3D, CD247, CD3G, LCK, PRKCQ, CD4 | More | | Cannabidiol | hsa05310 | Asthma | 2.71E-02 | 1 | P20036 | HLA-DPA1 | More | | Cannabidiol | hsa05320 | Autoimmune thyroid disease | 6.60E-03 | 5 | P13765, P20036, P29965, P01568, P10747 | HLA-DOB, HLA-DPA1, CD40LG, IFNA21, CD28 | More | | Cannabidiol | hsa05321 | Inflammatory bowel disease | 3.51E-04 | 5 | P01375, P20036, Q14765, Q9UL17, P23771 | TNF, HLA-DPA1, STAT4, TBX21, GATA3 | More | | Cannabidiol | hsa05322 | Systemic lupus erythematosus | 2.30E-05 | 6 | P09871, Q93077, P62807, P33778, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Cannabidiol | hsa05330 | Allograft rejection | 3.91E-04 | 3 | P20036, P48023, P01375 | HLA-DPA1, FASLG, TNF | More | | Cannabidiol | hsa05332 | Graft-versus-host disease | 8.73E-07 | 6 | P13765, P20036, P48023, P01375, P26715, Q13241 | HLA-DOB, HLA-DPA1, FASLG, TNF, KLRC1, KLRD1 | More | | Cannabidiol | hsa05340 | Primary immunodeficiency | 2.16E-04 | 6 | P01730, P01732, P16871, P04234, P07766, P06239 | CD4, CD8A, IL7R, CD3D, CD3E, LCK | More | | Cannabidiol | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Cannabidiol | hsa05415 | Diabetic cardiomyopathy | 5.56E-04 | 5 | P45880, P19404, Q06055, P12074, P04406 | VDAC2, NDUFV2, ATP5G2, COX6A1, GAPDH | More | | Cannabidiol | hsa05416 | Viral myocarditis | 4.49E-02 | 1 | P20036 | HLA-DPA1 | More | | Cannabidiol | hsa05418 | Fluid shear stress and atherosclerosis | 2.49E-03 | 11 | Q16539, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |